News from Karo Pharma

1 April, 2021

Karo Pharma completes the acquisition of the brand portfolio from Teva Pharmaceuticals

Karo Pharma Aktiebolag (“Karo”) today announces that the acquisition of the European OTC brand portfolio from Teva Pharmaceuticals (Teva) for 84 MEUR, which was signed and announced on 3 February 2021, has been completed. The transaction transfers ownership of the brand portfolio, comprised of Flux ®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to...

30 March, 2021

Karo Pharma publishes the 2020 annual report

Today, on 30 March 2021, Karo Pharma is publishing its annual report for 2020 on the company’s website, www.karopharma.com. For further information, please contact: Jon Johnsson, CFO, 073-507 88 61, jon.johnsson@karopharma.com The Annual Report is published in Swedish and English. The Swedish version represents the original version and has been translated into English. This information...

18 February, 2021

Year-end report 2020

Q4, October – December Net sales amounted to MSEK 721.2 (649.3). This corresponds to an increase of 11% for the period. The organic growth* during the fourth quarter was +1%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson...

3 February, 2021

Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals

Karo Pharma Aktiebolag (“Karo”) today announces the acquisition of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for a total consideration of EUR 84m.